Research
Molecular
GLP-1 receptor agonists can exist stably in patients for a long time, overcoming the short half-life of natural GLP-1.
Practitioners can expect longer-lasting effects from GLP-1 receptor agonists compared to natural GLP-1.
StrongSupportsmedium confidence
To a certain extent, they overcome the problem of the short half-life of natural GLP-1 in vivo and can exist stably in patients for a long time.
Why this rating
The claim is based on a review of recent research progress.
Source
The Discovery and Development of Glucagon-Like Peptide-1Receptor Agonists
Haowen Fang et al. · Current Medicinal Chemistry · 2023
reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →